Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 230

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 230
---
oryakhin received (i) £107,000, in lieu of his notice entitlement period, and (ii) a termination
payment of £30,000. Any option awards that had not vested as of the date of departure were forfeited.

Board of Directors

Our Board of Directors is
currently comprised of five directors, one of whom is an executive director and four of whom are non-executive directors, reflecting a
blend of different experience and backgrounds. The roles of Chairman of the Board of Directors (which is a non-executive position) and
Chief Executive Officer have been split and there is a clear division of responsibility between the two positions. With a view towards
maintaining the independence of the Board of Directors, no remuneration is paid to either the Chairman or non-executive directors in the
form of shares.

Effective as of September
28, 2018, all AIM quoted companies were required to formally apply a recognized corporate governance code. While we are no longer traded
on AIM, we have chosen to adopt the principles of the Quoted Companies Alliance Corporate Governance Code for Small and Mid-Sized Quoted
Companies, or the QCA Code. The QCA Code identifies ten principles to be followed in order for companies to deliver growth in long term
shareholder value, encompassing and efficient, effective and dynamic management framework, accompanied by good communication, to promote
confidence and trust.

The Board of Directors is responsible for inter alia, approving interim and annual financial statements, formulating and monitoring our strategy, approving financial plans and reviewing
performance, as well as complying with legal, regulatory and corporate governance matters. There is a schedule of matters reserved for
the Board of Directors.

The Board of Directors meets
regularly to consider strategy, performance and the framework of internal controls. To enable the Board of Directors to discharge its
duties, all directors receive appropriate and timely information. Briefing papers are distributed to all directors in advance of board
meetings.

Board Committees

We have established audit,
nomination, and remuneration committees of the Board of Directors with formally delegated duties and responsibilities. From time to time,
separate committees may be set up by the Board of Directors to consider specific issues when the need arises.

Audit Committee

The Audit Committee consists
of three members: Dr. Turton (Chairman), Dr. Parker and Ms. Merchant. During 2023, Dr. de Vries served on the Audit Committee until the
appointment of Ms. Merchant on January